NVDA vs PFE: Which Is the Better Buy?
Side-by-side comparison of NVIDIA Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
NVIDIA Corporation · Technology
$210.69
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
NVDA has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NVDA |
PFE |
| Current Price |
$210.69 |
$25.22 |
| Fair Value Estimate |
$305.50 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$5,103.1B |
$143.7B |
| Forward P/E |
32.1x
|
19.2x
|
| EV / EBITDA |
26.5x
|
12.3x
|
| Price / Sales |
20.1x
|
2.3x
|
| Price / FCF |
42.9x
|
15.2x
|
| Revenue Growth YoY |
+85.2%
|
+5.4%
|
| Gross Margin |
74.1%
|
69.3%
|
| Operating Margin |
64.0%
|
23.4%
|
| Return on Equity |
111.7%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.33%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
NVIDIA Corporation is a leading technology company specializing in semiconductors, particularly GPUs and AI accelerators, with a dominant market position in AI training markets holding over 80% share. The company exhibits exceptional business quality with a founder-led management team boasting over 30 years of continuous leadership, very high profitability with gross margins above 74% and net mar…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
NVDA |
PFE |
| Zone Low |
$229.12 |
$19.44 |
| Zone High |
$259.68 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|